Abstract
The overall goal of our previous reports was to emphasize the need to establish dedicated clinics focused on dystrophic cardiomyopathy [1,2]. We believe this is essential as Duchenne (DMD) and Becker muscular dystrophy (BMD) patient populations are underserved as the incidence of cardiomyopathy is nearly universal and results in heart failure progression [1,2]. We also emphasized the need for increased clinical and basic science research funding focused on dystrophic cardiomyopathy, the need for increased education related to this topic at national meetings such as the Heart Failure Society of America (HFSA) Annual Scientific Meeting and the AHA Annual Scientific Sessions and the need for a registry database that will enroll and longitudinally follow all patients with muscular dystrophies [2].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
